MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm

Los Angeles – On November 7, 2025, the national shareholder‑rights litigation firm Schall Law Firm reminded investors of the pending class‑action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) for alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act and Rule 10b‑5. Investors who purchased MoonLake securities between March 10, 2024 and September 29, 2025 — the defined “Class Period” — are encouraged to contact the firm by December 15, 2025 to discuss their rights. The complaint alleges that MoonLake made false or misleading statements about its drug candidate, sonelokimab (SLK), touting its superiority over other monoclonal antibodies despite lacking proven advantages. The company’s subsequent Phase 3 trial results, described by analysts as “disastrous”, reportedly led to a loss of nearly 90% in share value. As the truth emerged, investors allegedly suffered damages. Until certification of the class, participants are not yet represented by counsel and can either join or remain passive class members. #MoonLake #MLTX #SecuritiesFraud #ClassAction #SlimScan #GrowthStocks #CANSLIM